A recent virtual regulatory inspection hosted in Florida delivered some hope that the global pharmaceutical manufacturing sector and the authorities that regulate it can carry on in some semblance of a normal fashion despite the international travel restrictions resulting from the COVID-19 pandemic.
How The European Medicines Agency Inspected Thermo Fisher’s Florida Plant Without Leaving Europe
Contract development and manufacturing organization relied on combination of immersive mixed-reality devices to host remote inspection.
More from Manufacturing
• By
The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.
• By
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth
• By
The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
More from Compliance
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?